BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

...PD-1s” ). The company’s pipeline also includes three candidates in Phase III testing: anti-HER2 mAb GB221...
...Programmed cell death 1 TNFα - tumor necrosis factor α Hongjiang Li, Staff Writer Biosimilar trastuzumab (GB221) Biosimilar...
BioCentury | Jun 10, 2013
Company News

BIOCND Inc., Genor Biopharma deal

...Southeast and Northeast Asia (except Greater China) and Russia. It also granted BIOCND rights to GB221...
...I trial of GB232 and in early 2014 for a Phase III trial of GB221. GB221...
Items per page:
1 - 2 of 2